ES2552754T1 - Formulaciones de daptomicina y usos de la misma - Google Patents

Formulaciones de daptomicina y usos de la misma Download PDF

Info

Publication number
ES2552754T1
ES2552754T1 ES13837694.2T ES13837694T ES2552754T1 ES 2552754 T1 ES2552754 T1 ES 2552754T1 ES 13837694 T ES13837694 T ES 13837694T ES 2552754 T1 ES2552754 T1 ES 2552754T1
Authority
ES
Spain
Prior art keywords
pharmaceutically acceptable
daptomycin formulations
acceptable salts
daptomycin
formulations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
ES13837694.2T
Other languages
English (en)
Inventor
Jim ALEXIOU
Noel Norris
Andrew Knill
Darryl Whittaker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hospira Australia Pty Ltd
Original Assignee
Hospira Australia Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50277707&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2552754(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hospira Australia Pty Ltd filed Critical Hospira Australia Pty Ltd
Publication of ES2552754T1 publication Critical patent/ES2552754T1/es
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Una formulación de daptomicina liofilizada que comprende un aditivo seleccionado del grupo que consiste en antioxidantes farmacéuticamente aceptables, ácidos orgánicos farmacéuticamente aceptables y sales de los mismos farmacéuticamente aceptables, derivados de glucosa farmacéuticamente aceptables y sales de los mismos farmacéuticamente aceptables, y combinaciones de los mismos.
ES13837694.2T 2012-09-11 2013-09-11 Formulaciones de daptomicina y usos de la misma Pending ES2552754T1 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261699570P 2012-09-11 2012-09-11
US201261699570P 2012-09-11
US201361839699P 2013-06-26 2013-06-26
US201361839699P 2013-06-26
PCT/IB2013/002191 WO2014041425A1 (en) 2012-09-11 2013-09-11 Daptomycin formulations and uses thereof

Publications (1)

Publication Number Publication Date
ES2552754T1 true ES2552754T1 (es) 2015-12-02

Family

ID=50277707

Family Applications (2)

Application Number Title Priority Date Filing Date
ES13837694.2T Pending ES2552754T1 (es) 2012-09-11 2013-09-11 Formulaciones de daptomicina y usos de la misma
ES22169277T Active ES3018415T3 (es) 2012-09-11 2013-09-11 Formulaciones de daptomicina y usos de las mismas

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES22169277T Active ES3018415T3 (es) 2012-09-11 2013-09-11 Formulaciones de daptomicina y usos de las mismas

Country Status (21)

Country Link
US (4) US9655946B2 (es)
EP (2) EP2895187A4 (es)
AU (2) AU2013316779A1 (es)
BR (1) BR112015005400B1 (es)
CA (1) CA2884484C (es)
CL (1) CL2015000608A1 (es)
CY (1) CY2200004T2 (es)
DE (1) DE13837694T1 (es)
DK (1) DK2895187T1 (es)
ES (2) ES2552754T1 (es)
HK (1) HK1207006A1 (es)
HU (2) HUE071031T2 (es)
IL (1) IL237652B (es)
MX (1) MX366122B (es)
NZ (3) NZ741342A (es)
PL (1) PL4066849T3 (es)
SA (1) SA515360129B1 (es)
SG (1) SG11201506113WA (es)
TN (1) TN2015000090A1 (es)
WO (1) WO2014041425A1 (es)
ZA (1) ZA201502310B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9655946B2 (en) * 2012-09-11 2017-05-23 Hospira Australia Pty Ltd. Daptomycin formulations and uses thereof
MA37975B2 (fr) 2012-09-11 2021-03-31 Genzyme Corp Inhibiteurs de synthase de glucosylcéramide
WO2018073269A1 (en) 2016-10-21 2018-04-26 Xellia Pharmaceuticals Aps Liquid formulations of daptomycin
RU2770366C2 (ru) 2017-08-31 2022-04-15 Кселлия Фармасьютикалз Апс Препараты даптомицина
CN110339342A (zh) * 2018-04-03 2019-10-18 江苏恒瑞医药股份有限公司 一种达托霉素的盐或含盐的组合物及其制备方法
US11058745B1 (en) 2018-10-04 2021-07-13 Good Health, Llc Stable liquid pharmaceutical compositions of daptomycin
CN114040762A (zh) 2019-02-04 2022-02-11 建新公司 使用葡糖神经酰胺合酶(gcs)的抑制剂治疗纤毛疾病
JP7582205B2 (ja) * 2019-12-26 2024-11-13 ニプロ株式会社 ダプトマイシンを含有する安定した凍結乾燥製剤
JP2023512366A (ja) 2020-02-03 2023-03-27 ジェンザイム・コーポレーション リソソーム蓄積性疾患と関連する神経学的症状を処置するための方法
EP4117625A1 (en) 2020-03-12 2023-01-18 Baxter International Inc. Daptomycin formulations containing a combination of sorbitol and mannitol
AU2021311131B2 (en) 2020-07-24 2026-02-19 Genzyme Corporation Pharmaceutical compositions comprising venglustat
CN115590825B (zh) * 2022-10-20 2024-02-02 安士制药（中山）有限公司 一种注射用达托霉素及其制备方法
CN120478324B (zh) * 2025-04-28 2025-12-26 暨南大学 泛酸或其药学上可接受的盐在制备增强病原菌对达托霉素的敏感性的药物中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5560906A (en) * 1995-03-27 1996-10-01 Oral Technology Laboratories, Inc. Non-alcoholic antimicrobial mouthwash for removal of dental plaque
PL203689B1 (pl) * 1998-09-25 2009-11-30 Cubist Pharmaceuticals Zastosowanie daptomycyny
US6696412B1 (en) 2000-01-20 2004-02-24 Cubist Pharmaceuticals, Inc. High purity lipopeptides, Lipopeptide micelles and processes for preparing same
WO2002059145A1 (en) * 2000-12-18 2002-08-01 Cubist Pharmaceuticals, Inc. Methods for preparing purified lipopeptides
US7468428B2 (en) * 2004-03-17 2008-12-23 App Pharmaceuticals, Llc Lyophilized azithromycin formulation
CN1616083A (zh) * 2004-09-01 2005-05-18 魏雪纹 注射用达托霉素冻干制剂及制备方法
JP2008546429A (ja) * 2005-05-31 2008-12-25 キュービスト ファーマシューティカルズ， インコーポレイテッド バイオフィルム処理およびカテーテル救出のためのダプトマイシン
WO2011062676A1 (en) * 2009-11-23 2011-05-26 Eagle Pharmaceuticals, Inc. Formulations of daptomycin
RU2607526C2 (ru) 2009-11-23 2017-01-10 Кьюбист Фармасьютикалз ЭлЭлСи Липопептидные композиции и родственные способы
ES2655215T3 (es) * 2012-08-23 2018-02-19 Mylan Laboratories Ltd. Mejoramiento de la formulación inyectable de daptomicina
US9655946B2 (en) * 2012-09-11 2017-05-23 Hospira Australia Pty Ltd. Daptomycin formulations and uses thereof

Also Published As

Publication number Publication date
EP2895187A1 (en) 2015-07-22
AU2013316779A1 (en) 2015-04-02
TN2015000090A1 (en) 2016-06-29
US20200237858A1 (en) 2020-07-30
BR112015005400B1 (pt) 2022-03-08
AU2018217322B2 (en) 2020-08-27
NZ706286A (en) 2018-05-25
HUE13837694T1 (hu) 2016-04-28
ES3018415T3 (es) 2025-05-16
ZA201502310B (en) 2019-09-25
EP4066849C0 (en) 2025-03-05
AU2018217322A1 (en) 2018-09-06
CA2884484A1 (en) 2014-03-20
US20170216396A1 (en) 2017-08-03
MX366122B (es) 2019-06-27
US20180177843A1 (en) 2018-06-28
CL2015000608A1 (es) 2015-11-06
NZ741342A (en) 2019-10-25
DE13837694T1 (de) 2015-12-31
EP4066849B1 (en) 2025-03-05
NZ742241A (en) 2019-08-30
EP2895187A4 (en) 2015-12-02
DK2895187T1 (da) 2015-11-16
HK1207006A1 (en) 2016-01-22
CY2200004T2 (el) 2016-02-10
HUE071031T2 (hu) 2025-07-28
SG11201506113WA (en) 2015-09-29
US20150313958A1 (en) 2015-11-05
BR112015005400A2 (pt) 2017-07-04
US9655946B2 (en) 2017-05-23
IL237652A0 (en) 2015-04-30
PL4066849T3 (pl) 2025-06-16
WO2014041425A1 (en) 2014-03-20
CA2884484C (en) 2021-01-19
EP4066849A1 (en) 2022-10-05
IL237652B (en) 2020-06-30
MX2015003164A (es) 2015-12-16
SA515360129B1 (ar) 2016-08-15
US10357535B2 (en) 2019-07-23

Similar Documents

Publication Publication Date Title
ES2552754T1 (es) Formulaciones de daptomicina y usos de la misma
CL2023001911A1 (es) Derivado de glucagón y una composición que comprende un conjugado de acción prolongada del mismo
CL2017000984A1 (es) Reducción de la viscosidad de formulaciones farmacéuticas
CL2018003681A1 (es) Derivados de ácido borónico y usos terapéuticos de los mismos
UY35351A (es) Formulaciones acuosas estables de adalimumab
CR20140541A (es) Formulaciones farmacéuticas tópicas no acuosas
GT201400142A (es) Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
UY34617A (es) Composiciones veterinarias orales parasiticidas que comprenden agentes activos de acción sistémica, métodos y usos de las mismas
UY34772A (es) ?una formulación de fármaco de liberación retardada?.
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
UY34542A (es) ?formulaciones farmacéuticas para conjugados de derivados de fumagilina y phf?.
BR112016012146A8 (pt) derivados de aminopiridina como inibidores de quinase da família tam
CL2012002355A1 (es) Compuestos derivados de 1,3,4,8-tetrahidro-2h-pirido[1,2-a]pirazina; composicion farmaceutica que los comprende; kit farmaceutico; y su uso como inhibidores de la integrasa del vih para el tratamiento de una enfermedad infecciosa del vih.
UY35663A (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos
UY34605A (es) Derivados de arilalquiloxipirimidina e insecticidas agrohortícolas que comprenden dichos derivados como principios activos, y método de uso de los mismos
GT201600017A (es) Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
MX2016016583A (es) Derivados de indolizina como inhibidores de fosfoinositido-3 cinasas.
MX2018000280A (es) Oxiesteroles y metodos de uso de los mismos.
AR093645A1 (es) Una formulacion estabilizada de pemetrexed
MX2016007410A (es) Derivados del isocromeno como inhibidores de las fosfoinositido-3 cinasas.
MX2015012833A (es) Composiciones antibioticas de ceftolozano.
BR112017028549A2 (pt) derivados de pirimidina como inibidores de btk e usos dos mesmos
CO2017006958A2 (es) Formulaciones farmacéuticas que comprenden cangrelor de alta pureza y métodos para la preparación y uso de los mismos
PE20150167A1 (es) (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel
MX2016008841A (es) Moduladores heterociclicos de la sintesis de lipidos para su uso contra el cancer e infecciones virales.